Compare Organon & Co. Common Stock (OGN) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Vanguard S&P 500 Growth Index Fund ETF trades at $84.5 (market cap $27.10B). The key difference: Vanguard S&P 500 Growth Index Fund ETF is far larger — about 7.5× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Vanguard S&P 500 Growth Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Vanguard S&P 500 Growth Index Fund ETF for 56 Days on average.
| OGN | VOOG | |
|---|---|---|
Market Cap | $3.62B | $27.10B |
Volume | 2,892,999 | 775,650 |
Sector | Health | Broad Market / Factor |
52-Week High | $13.81 | $87.81 |
52-Week Low | $5.70 | $65.32 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
VOOG trades at $86.9, down slightly by 0.02% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF, tracking S&P 500 growth stocks, has seen strong institutional buying and positive media coverage highlighting its long-term growth potential and low expense ratio of 0.07%.
The outlook remains favorable for growth-oriented investors, supported by historical outperformance and sector concentration in technology. Key risks include market volatility and reliance on mega-cap tech stocks, but analyst sentiment and institutional inflows suggest continued confidence in its strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
